Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
25 enrolled 8 charts
Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
Phase 2 Completed
16 enrolled
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
26 enrolled 10 charts
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Phase 2 Withdrawn
EPICentro
Phase 2 Completed
28 enrolled
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Completed
22 enrolled
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
Phase 2 Completed
77 enrolled 15 charts
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Phase 2 Completed
36 enrolled 13 charts
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
Phase 2 Completed
56 enrolled
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Phase 2 Completed
60 enrolled
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Phase 2 Completed
18 enrolled 8 charts
Chemoradiation in Locally Advanced Pancreatic Cancer
Phase 2 Terminated
23 enrolled 8 charts
Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
Phase 2 Terminated
22 enrolled
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Phase 2 Terminated
87 enrolled
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Phase 2 Completed
36 enrolled 14 charts
Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon
Phase 2 Completed
36 enrolled
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
Phase 2 Completed
28 enrolled
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Phase 2 Withdrawn
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Phase 2 Withdrawn
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia
Phase 2 Completed
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Completed
30 enrolled
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Completed
Chemotherapy and Radiation Following Pancreatic Surgery
Phase 2 Completed
53 enrolled
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
Phase 2 Completed
Bone Marrow Transplantation in Treating Patients With Lymphoma
Phase 2 Completed
45 enrolled
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Phase 2 Completed
90 enrolled
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Phase 2 Terminated
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
Phase 2 Completed
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
Phase 2 Completed
29 enrolled 5 charts
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Completed
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
Phase 2 Completed
40 enrolled
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 2 Completed
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 2 Terminated
48 enrolled
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
Phase 2 Completed
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
Phase 2 Completed
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
Phase 2 Completed
40 enrolled
Biological Therapy in Treating Patients With Metastatic Cancer
Phase 2 Completed
30 enrolled
FR-WB-TT/che
Phase 2 Unknown
36 enrolled
FR-WB-TT
Phase 2 Unknown
36 enrolled
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Phase 2 Completed
35 enrolled
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
Phase 2 Completed
40 enrolled
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
Phase 2 Completed
12 enrolled
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
Phase 2 Completed
49 enrolled